Engineering High-Speed Pen Injector Pre-Assembly Machine: Overcoming Dimensional Variability in Multi-Component Mechanism Integration

The transition from traditional syringes to disposable pen injectors has fundamentally transformed the fill-finish and assembly landscape. While much of the industry's attention focuses on the final assembly, specifically the critical integration of the drug-filled cartridge into the pen body, the true mechanical complexity lies upstream. The pre-assembly of the pen injector mechanism is a high-speed, high-precision orchestration of up to 13 micro-components, requiring dimensional verification, orientation control, and real-time defect segregation at speeds of 160 pens per minute (PPM).¹

Unlike final assembly, which primarily manages the delicate glass-to-plastic interface, pre-assembly deals entirely with injection-molded plastic components. However, the inherent dimensional variability of molded plastics, combined with the functional requirements of the dose-setting and injection mechanisms, creates a unique set of engineering challenges that must be addressed through advanced automation and in-line metrology.²

This article explores the mechanical architecture, sensor integration, and validation protocols required to build a robust pen injector pre-assembly line capable of meeting the requirements of International Organization for Standardization (ISO) 11608,³ EU GMP Annex 11,⁴ and FDA 21 Code of Federal Regulations (CFR) Part 11.⁵

The Challenge of Multi-Component Integration

A standard disposable pen injector mechanism (used for insulin or GLP-1 delivery devices) consists of multiple interacting parts: the plunger cap, dial grip, clutch, lead screw, outer body, thread insert, dose setting knob (DSK), gears, plunger, drive sleeve, spring, and button.

At 160 PPM, the system has less than 400 milliseconds to load, verify, and assemble each component. The primary engineering challenge is managing the accumulated tolerance stack-up. Injection-molded components exhibit slight dimensional variations due to mold wear, cooling shrinkage, and material batch differences. If these variations are not monitored and compensated for during assembly, the resulting pen may exhibit dose inaccuracy, excessive injection force, or mechanical failure, all of which directly impact compliance with ISO 11608-1 dose accuracy requirements.³

Modular Cell-Based Architecture

To manage this complexity, modern pre-assembly lines utilize a modular, servo-driven architecture with electronic cam profiles. A typical high-speed configuration employs approximately 130 circulating pallets to move the assemblies through sequential verification stages organized into dedicated cells.¹

Cell 1: Core Mechanism Sub-Assembly

The process begins with the core injection mechanism. Vibratory bowl feeders with automatic clearing functions load the plunger cap, dial grip, clutch, and lead screw. The critical challenge here is orientation. The machine must insert the lead screw into the clutch in the correct orientation; an inverted lead screw would result in complete mechanism failure. Advanced lines utilize high-speed vision systems to verify the lead screw's orientation before assembly, rejecting any inverted components in real time.

Cell 2: Outer Body and Thread Insert

The system loads the outer body and presses the thread insert into place. The depth of the thread insert is critical for dose accuracy, as it directly affects the engagement geometry of the dose-setting mechanism. Linear variable differential transformers (LVDTs) are employed to measure the insertion depth with tolerances as tight as ±0.100 mm. Any assembly falling outside this window is immediately flagged for rejection.¹

Cell 3: Gear Integration and Angular Alignment

This cell handles the dose-setting mechanism, including the DSK and internal gears. The assembly of the plunger requires precise angular alignment. The large circular groove of the plunger must align with the axial position of the DSK's internal rib at an optimal angle of ~45°, with an allowable circumferential angular swing of just ±1°. This level of precision demands servo-controlled rotary indexing with closed-loop feedback.⁶

Cell 4: Final Mechanism Assembly

The drive sleeve, spring, and button are added, completing the mechanical linkage. A critical verification step occurs here: measuring the total height of the pre-assembled pen after compressing the button and spring. The reference total height must meet a strict tolerance (eg, 89.2 ± 0.15 mm). This measurement confirms that all internal components are correctly seated and that the spring force will deliver the specified injection force.

Cell 5: Final Inspection and Unloading

The fully assembled mechanisms undergo final visual and functional checks, zero-marking verification, and are then unloaded for transfer to the final assembly line where the drug-filled cartridge will be integrated.

Precision Verification: LVDT Networks and Machine Vision

The backbone of a reliable pre-assembly line is its in-process verification network. Relying solely on mechanical stops is insufficient for medical device manufacturing under current GMP expectations.⁴

LVDT networks provide continuous, analog positional feedback at every crucial insertion step. For instance, gear components typically have LVDT limit settings of ±0.200 mm to ±0.300 mm. If a component is seated too high (indicating an obstruction or oversized part) or too low (indicating a missing part or undersized component), the Programmable Logic Controller. records the deviation, triggers rejection, and logs the event with full traceability.

Machine vision. Although LVDTs handle depth and height verification, machine vision systems handle presence detection, orientation confirmation, and surface defect identification. High-speed cameras verify that components are present and correctly seated before the next component is added. For orientation-critical components like the lead screw, vision algorithms compare the component profile against a reference template in under 50 milliseconds.

Validation Through Challenge Parts Testing

In pharmaceutical equipment manufacturing, a system is only as good as its validation documentation. To prove that the pre-assembly line can reliably detect and reject defective components, manufacturers use “Challenge Parts” during the factory acceptance test and site acceptance test, following the ISPE GAMP5 lifecycle approach.⁷

A comprehensive challenge parts protocol includes intentionally defective components designed to trigger each sensor in the system:

• Increased height: Components with added material (screws or dowel pins) to simulate oversized parts or incomplete seating.
• Reduced height: Components with their tops or bottoms machined down to simulate undersized or missing parts.
• Wrong orientation: Components assembled in an inverted position to test the vision system's orientation detection capability.

During validation, these challenge parts are fed into the machine. The system must successfully identify and reject 100% of the challenge parts while continuing to process conforming parts without interruption. This rigorous testing, documented under GAMP5 and 21 CFR Part 11 guidelines, ensures that the equipment meets the stringent requirements of both EU GMP and FDA regulations.⁸

The Bridge to Final Assembly

The output of the pre-assembly line is a fully functional, empty pen injector mechanism. The precision achieved in this stage directly impacts the success of the final assembly line. If the pre-assembly height tolerances are not met, the final assembly machine will struggle to perform the delicate cartridge press-fit, leading to cracked glass or dose inaccuracies.

As pharmaceutical manufacturers and CDMOs scale up production of GLP-1 receptor agonists and next-generation insulins, the demand for robust, high-speed pre-assembly equipment continues to grow. By using modular cell-based architectures, integrating advanced LVDT and vision networks, and adhering to rigorous challenge-testing protocols, equipment manufacturers can deliver the reliability and throughput required for commercial-scale injectable drug delivery device production.

References

1. DROFEN Machinery. Automatic Insulin Injection Pen Pre-Assembly Machine. Available at: https://www.drofen-pharma.com/pharmaceutical-machine/pen-injector-assembly-line/automatic-insulin-injection-pen-assembly.html
2. U.S. Food and Drug Administration. Current Good Manufacturing Practice Requirements for Combination Products. FDA Guidance for Industry. 2017. Available at: https://www.fda.gov/media/90425/download
3. International Organization for Standardization. ISO 11608-1:2022. Needle-based injection systems for medical use, Part 1: Requirements and test methods. ISO; 2022.
4. European Commission. EU GMP Annex 11: Computerised Systems. EudraLex Volume 4. 2011. Available at: https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf
5. US Food and Drug Administration. Part 11, electronic records; electronic signatures—scope and application: guidance for industry. Published August 2003. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/part-11-electronic-records-electronic-signatures-scope-and-application
6. DROFEN Machinery. Engineering Guide: Pen Injector Pre-Assembly Machine. Available at: https://www.drofen-pharma.com/info/injector-pre-assembly-machine-103542051.html
7. International Society for Pharmaceutical Engineering. GAMP 5: A Risk-Based Approach to Compliant GxP Computerized Systems. 2nd ed. ISPE; 2022.
8. DROFEN Machinery. The Complete Technical Guide to Injection Pen Assembly Lines: Pre-Assembly, Final Assembly, Functional Testing, and GMP Validation. Available at: https://www.drofen-pharma.com/info/the-complete-technical-guide-to-injection-pen-103559400.html